Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Patch could make opioid treatment start easier for pregnant women

NCT ID NCT05790252

Symptom relief Sponsor: Washington University School of Medicine Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 11, 2026 · Updated 2 times

Summary

This study tests whether a buprenorphine patch can reduce withdrawal symptoms when pregnant women with opioid use disorder start sublingual buprenorphine treatment. Forty participants will receive either a real patch or a sham bandage during the initial withdrawal period. Researchers will track withdrawal severity and treatment success through phone surveys and urine tests.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
buprenorphine transdermal patch
What this could lead to
If it works, this could offer a more comfortable way to start buprenorphine treatment for pregnant women with opioid use disorder, reducing withdrawal symptoms.
What could go wrong
This is a small early-phase trial with only 40 participants, so results may not apply to everyone. The patch might not reduce withdrawal better than current methods.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

7 people

The number who actually took part.

Started

Nov 2023

Finished

Aug 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 110 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Viable pregnancy * Meet diagnostic criteria for opioid use disorder * Receive prenatal care through opioid use disorder specific clinic at our institution * Opioid use within 24 hours prior to presentation * Desire treatment with buprenorphine Exclusion Criteria: * Patients already receiving treatment for opioid use disorder * History of prior induction attempt with buprenorphine * Active withdrawal at time of presentation * Medical contraindication to buprenorphine * Requiring immediate hospitalization

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Buprenorphine withdrawal are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

opiate dependence pregnancy disorder substance withdrawal syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Buprenorphine withdrawal Opioid use disorder Pregnancy complications Pregnancy related Pregnancy, high risk

Contacts and locations

Locations

  • Washington University in St. Louis

    St Louis, Missouri, 63124, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.